<SEC-DOCUMENT>0001753926-25-000123.txt : 20250123
<SEC-HEADER>0001753926-25-000123.hdr.sgml : 20250123
<ACCEPTANCE-DATETIME>20250123180821
ACCESSION NUMBER:		0001753926-25-000123
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250123
DATE AS OF CHANGE:		20250123

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIPELLA PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001347242
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93847
		FILM NUMBER:		25551181

	BUSINESS ADDRESS:	
		STREET 1:		400 N LEXINGTON ST
		STREET 2:		STE LL103
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15208
		BUSINESS PHONE:		412-901-0315

	MAIL ADDRESS:	
		STREET 1:		400 N LEXINGTON ST
		STREET 2:		STE LL103
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15208

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIPELLA PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20051219

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kaufman Jonathan H
		CENTRAL INDEX KEY:			0001959250
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		C/O LIPELLA PHARMACEUTICALS INC.
		STREET 2:		7800 SUSQUEHANNA ST., SUITE 505
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15208
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001753926-22-001652</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Kaufman Jonathan H -->
          <cik>0001959250</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>10</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <dateOfEvent>01/21/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001347242</issuerCIK>
        <issuerCUSIP>53630L209</issuerCUSIP>
        <issuerName>Lipella Pharmaceuticals Inc.</issuerName>
        <address>
          <com:street1>7800 Susquehanna St., Suite 505</com:street1>
          <com:city>Pittsburgh</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>15208</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>David E. Danovitch, Esq.</personName>
          <personPhoneNum>(212) 660-3000</personPhoneNum>
          <personAddress>
            <com:street1>Sullivan &amp; Worcester LLP</com:street1>
            <com:street2>1251 Avenue of the Americas,19th Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10020</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001959250</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Jonathan H. Kaufman</reportingPersonName>
        <fundType>PF</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>212289.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>212289.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>212289.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>11.7</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Beneficial ownership consists of (i) 112,352 shares of common stock, par value $0.0001 per share, of the issuer (''Common Stock'') purchased by Dr. Jonathan Kaufman (the ''Reporting Person'') with personal funds and (ii) 99,937 shares of Common Stock that may be issued upon exercise of fully vested stock options awarded by the issuer (the ''Issuer'') to the Reporting Person in his capacity as an officer and director of the Issuer. The numbers and percentage listed in rows 7, 9, 11 and 13 above are based on 1,719,222 shares of Common Stock outstanding as of the date of this Amendment No. 10 to Statement on Schedule 13D (''Amendment No. 10''), as verified with the Issuer.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.0001 per share</securityTitle>
        <issuerName>Lipella Pharmaceuticals Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>7800 Susquehanna St., Suite 505</com:street1>
          <com:city>Pittsburgh</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>15208</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 10 amends and supplements the Statement on Schedule 13D initially filed by the Reporting Person with the U.S. Securities and Exchange Commission ("SEC") on December 29, 2022, as amended by Amendment No. 1 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on June 21, 2023, as amended by Amendment No. 2 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on March 6, 2024, as amended by Amendment No. 3 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on March 15, 2024, as amended by Amendment No. 4 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on March 19, 2024, as amended by Amendment No. 5 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on May 6, 2024, as amended by Amendment No. 6 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on October 17, 2024, as amended by Amendment No. 7 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on December 27, 2024, as amended by Amendment No. 8 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on January 3, 2025 and as amended by Amendment No. 9 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on January 17, 2025 (collectively, the "Schedule 13D"). Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D. Except as otherwise set forth herein, this Amendment No. 10 does not modify any of the information previously reported by the Reporting Person in the Schedule 13D. The purpose of this Amendment No. 10 is to update the Reporting Person's beneficial ownership information in the Schedule 13D. Except as specifically amended below, all other provisions of the Schedule 13D remain in effect.</commentText>
      </item1>
      <item2>
        <filingPersonName>Jonathan H. Kaufman</filingPersonName>
        <principalBusinessAddress>7800 Susquehanna Street, Suite 505, Pittsburgh, Pennsylvania 15208</principalBusinessAddress>
        <principalJob>President, Chief Executive Officer, Secretary, Treasurer and Chairman of the Board of Directors of the Issuer.</principalJob>
        <hasBeenConvicted>The Reporting Person has not been, during the last five years, convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>The Reporting Person has not been, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding of any violation with respect to such laws.</convictionDescription>
        <citizenship>The Reporting Person is a citizen of the United States of America.</citizenship>
      </item2>
      <item3>
        <fundsSource>The information contained in "Item 3. Source or Amount of Funds or Other Consideration." of the Schedule 13D is not being amended by this Amendment No. 10.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover page of this Amendment No. 10 and the corresponding comment, and the information set forth in or incorporated by reference into Item 2, Item 3, Item 5, Item 6 and Item 7 of this Amendment No. 10 is hereby incorporated by reference in its entirety into this Item 4. Except as described in this Item 4 above, the information contained in "Item 4. Purpose of Transaction." of the Schedule 13D is not being amended by this Amendment No. 10.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>See responses to rows 11 and 13 on the cover page of this Amendment No. 10.</percentageOfClassSecurities>
        <numberOfShares>See responses to rows 7, 8, 9 and 10 on the cover page of this Amendment No. 10.</numberOfShares>
        <transactionDesc>Except as otherwise set forth in the Schedule 13D, the Reporting Person has not, to the best of his knowledge, engaged in any transaction with respect to the Common Stock of the Issuer during the sixty days prior to the date of filing this Amendment No. 10.</transactionDesc>
        <listOfShareholders>To the knowledge of the Reporting Person, no person other than the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock of the Issuer beneficially owned by the Reporting Person as reported in the Schedule 13D.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>The information contained in "Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer." of the Schedule 13D is not being amended by this Amendment No. 10.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>The information contained in "Item 7. Material to be filed as Exhibits." of the Schedule 13D is not being amended by this Amendment No. 10.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Jonathan H. Kaufman</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Jonathan H. Kaufman</signature>
          <title>Jonathan H. Kaufman</title>
          <date>01/23/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
